cefuzonam has been researched along with Intestinal-Perforation* in 1 studies
1 trial(s) available for cefuzonam and Intestinal-Perforation
Article | Year |
---|---|
[Clinical studies on cefuzonam for acute peritonitis due to perforated appendicitis. Tissue concentration and clinical efficacy].
A clinical study on cefuzonam (CZON), a new parenteral cephalosporin antibiotic, was performed in 22 patients with acute appendicitis. CZON in a dose of 1 g was administered by intravenous bolus injection or intravenous drip infusion for 60 minutes. In the appendices, concentrations of CZON were 0.066-21.7 micrograms/g in normal or slight catarrhal cases, 0.173-11.7 micrograms/g in moderate phlegmous cases and 0.116-12.1 micrograms/g in serious gangrenous perforated cases. The concentration of CZON in appendixes was not directly proportional to the degree of pathological change of inflammation. 6 patients with acute peritonitis due to perforated appendicitis were treated with CZON of 2 g/day for 5-10 days. The clinical effect was good in 5 cases, fair in 1 case of the above 6. The clinical efficacy rate was 83%. Side effects were not notable in the patients. Topics: Acute Disease; Adolescent; Adult; Aged; Appendicitis; Ceftizoxime; Child; Female; Humans; Infusions, Intravenous; Intestinal Perforation; Male; Middle Aged; Peritonitis; Rupture, Spontaneous | 1991 |